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Cardiovascular disease (CVD) is still the leading cause of death worldwide. 1 The underlying pathology for the majority of CVD is atherosclerosis, a chronic, dyslipidaemia-driven systemic inflammatory disease that leads to the formation of atherosclerotic plaques. Innate and adaptive immune responses play a crucial role in the complex pathogenesis of atherosclerotic disease. By converting immune cells into pro-and anti-inflammatory chemokine and cytokine producing units, and by regulating the interactions between the different immune cells, the immune system critically influences disease progression and thereby the propensity of a given plaque to undergo erosion or rupture and cause clinical symptoms like myocardial infarction and stroke. 2 The recent study from Duchene et al. 3 provides intriguing novel insights into the understanding of chemokine biology, and its importance for leukocyte function. The starting point of their research was the fact that healthy individuals of African ancestry show a characteristic phenotype of low blood neutrophil counts, named as 'ethnic neutropenia'. Given that neutrophils are the most abundant leukocyte subtype in humans, and playing a pivotal role in inflammatory responses, 7 the fundamental findings by Duchene et al. 3 deserve to be highlighted in the context of atherosclerosis and other CVD entities with an inflammatory component, such as aneurysms or heart failure. In early stages of atherogenesis, neutrophils are activated through platelet-derived CCL5 and adhere along the arteries followed by the release of signal molecules that promote adhesion and recruitment of monocytes. Throughout the course of disease progression, neutrophils secrete mediators that activate macrophages to produce inflammatory cytokines, exemplifying the virtues of innate immunity, but also its chronic perpetuation. 7 Also perivascular inflammation of adipose tissue, mediated through recruitment of immune cells, has been shown to contribute to the progression of atherosclerotic disease. 8 Notably, atherosclerosis is only one-albeit prominent-example of CVD pathogenesis where inflammatory processes contribute to disease progression and severity. Sun et al. recently summarized the role of cardiac inflammation in right ventricular failure. Although clinical evidence is still limited, available human and experimental data suggest that both systemic (e.g. neurohormonal) and local (e.g. shear) stresses trigger inflammatory responses, reflected by an increase in leukocytes (e.g. macrophages, neutrophils) and increased circulating levels of inflammatory cytokines [tumour necrosis factor-a, interleukin (IL)-1ß and IL-6], and chemokines (i.e. CCL5 and CXCL16) that are known to impair cardiac contractility and remodelling in pulmonary arterial hypertension and related heart failure. 9 The exact processes whereby neutrophils contribute to inflammatory responses in heart failure remain elusive but deserve attention in future research.
Intriguing support for a role for innate immunity in human CVD was recently provided by the results from the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS). CANTOS is a doubleblind trial including high-risk patients with prior myocardial infarction and an increased inflammatory response (high-sensitivity C-reactive protein (hsCRP) levels > 2 mg/L), who were randomized to canakinumab (50, 150, or 300 mg) or placebo treatment. 10 Canakinumab is a human monoclonal antibody targeting IL-1ß, a master cytokine of innate immunity and key regulator of neutrophil and macrophage recruitment. Canakinumab treatment effectively reduced circulating hsCRP and IL-6 levels, without effecting circulating blood lipids. Most strikingly, after a median follow-up of 3.7 years, the incidence rate for the primary composite end point of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death was significantly reduced by 15% in the 150 mg-group [hazard ratio (HR) (95% confidence interval) 0.85 (0.74-0.98); P = 0.021] and 14% in the 300-mg group [HR 0.86 (0.75-0.99); P = 0.031]. These results will eventually change the landscape of cardiovascular research, as this is the first proof of concept that anti-inflammatory treatment is beneficial for cardiovascular outcome in humans.
A growing number of genome-wide association studies identified and validated genetic variants that are associated with CVD. 11 However, the impact of defined 'genomic stress', e.g. neutrophil alterations through ACKR1 deficiency, on the various forms of inflammatory CVD is still enigmatic. Here, it would be intriguing to follow-up the approach of Duchene et al., 3 and to elucidate the role of ACKR1 and ACKR1-mediated effects on immune cells in the diverse pathogeneses of CVDs, for instance by subjecting Duchene's ACKR1 mice to diverse experimental models of CVD (e.g. atherosclerosis, pressure overload-induced cardiac hypertrophy, ischaemia/reperfusion). Additionally, the role of neutrophils in human CVD needs to be defined better. These results will eventually help to decipher cardiovascular disease entities that might be responsive for anti-inflammatory treatment.
In conclusion, Duchene et al. 3 provide exciting insights into the understanding of chemokine biology, and its importance for leukocyte function that might play a crucial role in the pathogenesis of atherosclerosis and other CVD, particularly in Duffy-negative individuals of African descent carrying a ACKR1 gene variant. Accordingly, the recent results from the CANTOS trial strongly support the inflammatory hypothesis of atherosclerotic disease. These novel findings potentially open a new avenue for personalized-genotype and phenotype dependent-treatment in atherosclerosis. By incorporating genomic information, phenotype, and specific biomarkers to identify appropriately selected patient subgroups, CV risk stratification and accordingly guided therapy may achieve the optimal benefit from anti-inflammatory treatment.
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